Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carsten Bokemeyer

Showing results (601-610 of 664) with videos related to

Pageof 67
Sort By:
The Journal of Clinical Investigation|February 3, 2026
Overexpression of the ERG oncogene in prostate cancer identifies candidates for PARP inhibitor-based radiosensitizationSabrina Köcher, Mohamed E Elsesy, Ayham Moustafa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 27, 2019
Outcome of Men With Relapses After Adjuvant Bleomycin, Etoposide, and Cisplatin for Clinical Stage I NonseminomaStefanie Fischer, Torgrim Tandstad, Gabriella Cohn-Cedermark, et al.
Blood|August 29, 2013
Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stromaIsabel Ben-Batalla, Alexander Schultze, Mark Wroblewski, et al.
Der Pathologe|December 1, 2020
[Diagnosis and therapy of tumors with NTRK gene fusion]Albrecht Stenzinger, Cornelis M van Tilburg, Ghazaleh Tabatabai, et al.
European Journal of Cancer (Oxford, England : 1990)|October 1, 2018
Clinicopathological differences and survival outcomes with first-line therapy in patients with left-sided colon cancer and rectal cancer: Pooled analysis of 2879 patients from AGITG (MAX), COIN, FOCUS2, OPUS, CRYSTAL and COIN-B trials in the ARCAD databaseMohamed E Salem, Jun Yin, Benjamin A Weinberg, et al.
International Journal of Cancer|May 16, 2026
Molecular Tumor Boards in Malignant Melanoma: Uncovering Challenges and Opportunities in a Bicenter Retrospective Analysis in GermanyGlenn Geidel, Theresa Lowinus, Patrick Metzger, et al.
International Journal of Cancer|December 24, 2015
The marine triterpene glycoside frondoside A exhibits activity in vitro and in vivo in prostate cancerSergey A Dyshlovoy, Ekaterina S Menchinskaya, Simone Venz, et al.
International Journal of Cancer|November 26, 2009
NY-CO-58/KIF2C is overexpressed in a variety of solid tumors and induces frequent T cell responses in patients with colorectal cancerSacha Gnjatic, Yanran Cao, Uta Reichelt, et al.
Cardio-Oncology (London, England)|July 4, 2025
Cardiac biomarkers for risk stratification in newly diagnosed high-risk multiple myeloma in the GMMG-CONCEPT trialLisa B Leypoldt, Linlin Guo, Britta Besemer, et al.
Cancer Immunology Research|November 11, 2024
Inflammatory Stress Determines the Need for Chemotherapy in Patients with HER2-Positive Esophagogastric Adenocarcinoma Receiving Targeted Therapy and ImmunotherapyJoseph Tintelnot, Lisa Paschold, Eray Goekkurt, et al.
Pageof 67

Showing results (601-610 of 664) with videos related to

Sort By:
Pageof 67
The Journal of Clinical Investigation|February 3, 2026
Overexpression of the ERG oncogene in prostate cancer identifies candidates for PARP inhibitor-based radiosensitizationSabrina Köcher, Mohamed E Elsesy, Ayham Moustafa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 27, 2019
Outcome of Men With Relapses After Adjuvant Bleomycin, Etoposide, and Cisplatin for Clinical Stage I NonseminomaStefanie Fischer, Torgrim Tandstad, Gabriella Cohn-Cedermark, et al.
Blood|August 29, 2013
Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stromaIsabel Ben-Batalla, Alexander Schultze, Mark Wroblewski, et al.
Der Pathologe|December 1, 2020
[Diagnosis and therapy of tumors with NTRK gene fusion]Albrecht Stenzinger, Cornelis M van Tilburg, Ghazaleh Tabatabai, et al.
European Journal of Cancer (Oxford, England : 1990)|October 1, 2018
Clinicopathological differences and survival outcomes with first-line therapy in patients with left-sided colon cancer and rectal cancer: Pooled analysis of 2879 patients from AGITG (MAX), COIN, FOCUS2, OPUS, CRYSTAL and COIN-B trials in the ARCAD databaseMohamed E Salem, Jun Yin, Benjamin A Weinberg, et al.
International Journal of Cancer|May 16, 2026
Molecular Tumor Boards in Malignant Melanoma: Uncovering Challenges and Opportunities in a Bicenter Retrospective Analysis in GermanyGlenn Geidel, Theresa Lowinus, Patrick Metzger, et al.
International Journal of Cancer|December 24, 2015
The marine triterpene glycoside frondoside A exhibits activity in vitro and in vivo in prostate cancerSergey A Dyshlovoy, Ekaterina S Menchinskaya, Simone Venz, et al.
International Journal of Cancer|November 26, 2009
NY-CO-58/KIF2C is overexpressed in a variety of solid tumors and induces frequent T cell responses in patients with colorectal cancerSacha Gnjatic, Yanran Cao, Uta Reichelt, et al.
Cardio-Oncology (London, England)|July 4, 2025
Cardiac biomarkers for risk stratification in newly diagnosed high-risk multiple myeloma in the GMMG-CONCEPT trialLisa B Leypoldt, Linlin Guo, Britta Besemer, et al.
Cancer Immunology Research|November 11, 2024
Inflammatory Stress Determines the Need for Chemotherapy in Patients with HER2-Positive Esophagogastric Adenocarcinoma Receiving Targeted Therapy and ImmunotherapyJoseph Tintelnot, Lisa Paschold, Eray Goekkurt, et al.
Pageof 67